India · Delayed Price · Currency is INR Nephro Care India Statistics
Total Valuation
NSE:NEPHROCARE has a market cap or net worth of INR 1.37 billion. The enterprise value is 1.20 billion.
| Market Cap | 1.37B |
| Enterprise Value | 1.20B |
Important Dates
The next estimated earnings date is Friday, November 13, 2026.
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NSE:NEPHROCARE has 16.49 million shares outstanding. The number of shares has increased by 3.45% in one year.
| Current Share Class | 16.49M |
| Shares Outstanding | 16.49M |
| Shares Change (YoY) | +3.45% |
| Shares Change (QoQ) | -0.34% |
| Owned by Insiders (%) | 61.44% |
| Owned by Institutions (%) | n/a |
| Float | 6.36M |
Valuation Ratios
The trailing PE ratio is 24.29.
| PE Ratio | 24.29 |
| Forward PE | n/a |
| PS Ratio | 1.36 |
| PB Ratio | 2.40 |
| P/TBV Ratio | 2.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 61.90 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 21.40 |
| EV / Sales | 1.20 |
| EV / EBITDA | 10.08 |
| EV / EBIT | 19.39 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.02, with zero debt.
| Current Ratio | 2.02 |
| Quick Ratio | 1.48 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 126.99 |
Financial Efficiency
Return on equity (ROE) is 6.10% and return on invested capital (ROIC) is 10.95%.
| Return on Equity (ROE) | 6.10% |
| Return on Assets (ROA) | 3.74% |
| Return on Invested Capital (ROIC) | 10.95% |
| Return on Capital Employed (ROCE) | 7.34% |
| Weighted Average Cost of Capital (WACC) | 12.87% |
| Revenue Per Employee | 2.44M |
| Profits Per Employee | 136,199 |
| Employee Count | 413 |
| Asset Turnover | 1.26 |
| Inventory Turnover | 23.87 |
Taxes
In the past 12 months, NSE:NEPHROCARE has paid 22.73 million in taxes.
| Income Tax | 22.73M |
| Effective Tax Rate | 28.78% |
Stock Price Statistics
The stock price has decreased by -39.90% in the last 52 weeks. The beta is 1.57, so NSE:NEPHROCARE's price volatility has been higher than the market average.
| Beta (5Y) | 1.57 |
| 52-Week Price Change | -39.90% |
| 50-Day Moving Average | 90.08 |
| 200-Day Moving Average | 82.05 |
| Relative Strength Index (RSI) | 40.91 |
| Average Volume (20 Days) | 19,100 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:NEPHROCARE had revenue of INR 1.01 billion and earned 56.25 million in profits. Earnings per share was 3.42.
| Revenue | 1.01B |
| Gross Profit | 546.31M |
| Operating Income | 62.10M |
| Pretax Income | 78.98M |
| Net Income | 56.25M |
| EBITDA | 119.37M |
| EBIT | 62.10M |
| Earnings Per Share (EPS) | 3.42 |
Balance Sheet
The company has 165.02 million in cash and no debt, with a net cash position of 165.02 million or 10.01 per share.
| Cash & Cash Equivalents | 165.02M |
| Total Debt | n/a |
| Net Cash | 165.02M |
| Net Cash Per Share | 10.01 |
| Equity (Book Value) | 569.03M |
| Book Value Per Share | 34.53 |
| Working Capital | 155.11M |
Cash Flow
In the last 12 months, operating cash flow was 22.11 million and capital expenditures -78.06 million, giving a free cash flow of -55.96 million.
| Operating Cash Flow | 22.11M |
| Capital Expenditures | -78.06M |
| Depreciation & Amortization | 57.27M |
| Net Borrowing | n/a |
| Free Cash Flow | -55.96M |
| FCF Per Share | -3.39 |
Margins
Gross margin is 54.31%, with operating and profit margins of 6.17% and 5.59%.
| Gross Margin | 54.31% |
| Operating Margin | 6.17% |
| Pretax Margin | 7.85% |
| Profit Margin | 5.59% |
| EBITDA Margin | 11.87% |
| EBIT Margin | 6.17% |
| FCF Margin | n/a |
Dividends & Yields
NSE:NEPHROCARE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -3.45% |
| Shareholder Yield | -3.45% |
| Earnings Yield | 4.12% |
| FCF Yield | -4.09% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 6 |